Exabis Library
Welcome to the e-CCO Library!
DOP58: IdeaL: a multi-centre prospective infliximab dose to level pharmacokinetic study during induction in paediatric Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP58: Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in Ulcerative Colitis: A post-hoc analysis of individual level data from golimumab clinical trials
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP58: predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP58: predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP59: Development of a novel Ulcerative Colitis (UC) endoscopic activity prediction model using machine learning (ML)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP59: Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP59: Integration of in silico analysis and in vitro functional analysis reveals Tissue Factor Pathway Inhibitor 2 (TFPI2) as a master transcriptional regulator and potential target to impede Infliximab resistance in adult UC patients
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP59: Maintenance of remission with tofacitinib in patients with Ulcerative Colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP59: Maintenance of remission with tofacitinib in patients with Ulcerative Colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP59: Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP59: Proactive Infliximab Drug Monitoring Is Superior To Conventional Management In Inflammatory Bowel Disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP59: What is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participants
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP59: What is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participants
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP60: Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP60: Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP60: Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER Study
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM